Franklin Resources Inc Vir Biotechnology, Inc. Transaction History

Franklin Resources Inc

$346 Billion
Q3 2024

A detailed history of Franklin Resources Inc transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Franklin Resources Inc holds 97,948 shares of VIR stock, worth $660,169. This represents 0.0% of its overall portfolio holdings.

Number of Shares

97,948

Previous 100,181 2.23%

Holding current value

$660,169

Previous $891,000 17.73%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$7.26 - $10.7 $16,211 - $23,893	-2,233 Reduced 2.23%	97,948 $733,000
Q2 2024 Aug 14, 2024	SELL	$7.63 - $12.66 $20,700 - $34,346	-2,713 Reduced 2.64%	100,181 $891,000
Q1 2024 May 13, 2024	BUY	$8.6 - $11.9 $757,273 - $1.05 Million	88,055 Added 593.4%	102,894 $1.04 Million
Q4 2023 Feb 09, 2024	SELL	$7.76 - $10.29 $7,255 - $9,621	-935 Reduced 5.93%	14,839 $149,000
Q3 2023 Nov 13, 2023	SELL	$9.14 - $24.62 $132,593 - $357,162	-14,507 Reduced 47.91%	15,774 $147,000
Q2 2023 Aug 11, 2023	BUY	$23.2 - $27.29 $420,662 - $494,822	18,132 Added 149.25%	30,281 $742,000
Q1 2023 May 12, 2023	BUY	$22.26 - $30.85 $48,192 - $66,790	2,165 Added 21.68%	12,149 $282,000
Q4 2022 Feb 10, 2023	BUY	$19.96 - $28.22 $199,280 - $281,748	9,984 New	9,984 $252,000
Q2 2022 Aug 11, 2022	SELL	$19.08 - $26.7 $61,055 - $85,440	-3,200 Reduced 25.74%	9,230 $235,000
Q1 2022 May 13, 2022	SELL	$21.19 - $40.01 $4,873 - $9,202	-230 Reduced 1.82%	12,430 $320,000
Q4 2021 Feb 11, 2022	BUY	$30.97 - $54.03 $392,080 - $684,019	12,660 New	12,660 $530,000

Others Institutions Holding VIR

# of Institutions

219

Shares Held

87.4M

Call Options Held

127K

Put Options Held

1.19M

View Full List

About Vir Biotechnology, Inc.

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $894M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

More about VIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

News

Stay updated on Franklin Resources Inc with notifications on news.

Account

Franklin Resources Inc Vir Biotechnology, Inc. Transaction History